Clinical trialNCT01830985CompletedPhase 2/PHASE3Interventional

A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis

SponsorVertex Pharmaceuticals IncorporatedEnrollment39Rheumatoid Arthritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed to evaluate the long-term safety and tolerability of VX-509 in subjects with active rheumatoid arthritis (RA) on DMARD therapy. This study will enroll subjects who completed a previous designated study with VX-509 (e.g., Study VX12-509-103).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Bradley Bloom, MD, FACR, FAAP
Vertex Pharmaceuticals Incorporated
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Estonia

Vertex Investigational Site
Tallinn, Estonia

Lithuania

Vertex Investigational Site
Vilnius, Lithuania

South Africa

Vertex Investigational Site
Pretoria, South Africa
Vertex Investigational Site
Stellenbosch, South Africa

United States

Vertex Investigational Site
Upland, California, United States
Vertex Investigational Site
Fort Lauderdale, Florida, United States
Vertex Investigational Site
Venice, Florida, United States
Vertex Investigational Site
West Palm Beach, Florida, United States
Vertex Investigational Site
Canton, Georgia, United States
Vertex Investigational Site
Decatur, Georgia, United States
Vertex Investigational Site
Elizabethtown, Kentucky, United States
Vertex Investigational Site
Fredrick, Maryland, United States
Vertex Investigational Site
Lincoln, Nebraska, United States
Vertex Investigational Site
Rochester, New York, United States
Vertex Investigational Site
Greensboro, North Carolina, United States
Vertex Investigational Site
Duncansville, Pennsylvania, United States
Vertex Investigational Site
Charleston, South Carolina, United States
Vertex Investigational Site
Memphis, Tennessee, United States
Vertex Investigational Site
Katy, Texas, United States
Vertex Investigational Site
San Antonio, Texas, United States
Vertex Investigational Site
Webster, Texas, United States
Vertex Investigational Site
Spokane, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

VX-509

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2013
Primary completion: 31 Jul 2014
Completion: 31 Jul 2014
Last update posted: 20 Nov 2015
Registered enrollment: 39
Registry id: NCT01830985

Cross-registrations

EU-CTR / CTIS (EudraCT)2012-004342-14

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.